Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 1217 - 1224 of 12142 results

FTC Complaint Against Rite Aid Signals New Paradigm for Evaluating AI Technology Use
January 30, 2024| Blog| Viewpoint

New Year, New Privacy Law in New Jersey
January 30, 2024| Blog| Viewpoint

401k Plan Sponsors Must Be Wary Of Fiduciary Liability Associated With Bitcoin ETFs
January 30, 2024| News

Senator's Hold on FTC Nominee Robs Agency of Political Diversity, Regulatory Attorneys Say
January 29, 2024| News

OCR Releases Long Awaited Final Rule Regarding the Conscience Protections for Religious and Moral Objections in Health Care
January 29, 2024| Blog| Viewpoint

NERC Submits Work Plan for New Reliability Requirements to Apply to Inverter-Based Resources
January 26, 2024| Article| Viewpoint

What You Need to Know About FDA's Proposed Regulation of LDTs
January 26, 2024| News
News & Press Releases
Mintz Advises Point72 and Tsunami Express Car Wash in Acquisition of 53 Car Wash Locations from Whistle Express Car Wash
September 16, 2025
Mintz advised Point72 and Tsunami Express Car Wash, its portfolio company, in Tsunami’s acquisition of 53 car wash locations from Whistle Express Car Wash, which is owned by affiliates of Oaktree Capital Management.
Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber
September 15, 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Events
Podcasts

Mintz On Air: Practical Policies – DEI Developments: The Proxy Problem
September 16, 2025| Podcast|

Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|

Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
